Dipeptidyl Peptidase-IV Activity and/or Structure Homologs (DASH): Contributing Factors in the Pathogenesis of Rheumatic Diseases?

Balážiová, Eva; Šedová, Liliana; Mareš, V; Vlasicova, Kvetoslava; Ševčı́k, Jan; Šedo, Aleksi

doi:10.1007/0-387-32824-6_18

Cited by 5 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The exclusion criteria were age above 75 years and occurrence of any of the following states during the whole study: pregnancy, acute decompensation of diabetes, HbA1c above 9% (NGSP standardization) resp.75 mmol/mol (IFCC standardization), infections requiring antibiotic treatment, chronic inflammatory and autoimmune diseases and active allergy, neoplastic diseases, liver surface DPP-IV-like enzymatic activity in BMNC was determined as the activity of viable cells, the total DPP-IV-like enzymatic activity was measured under the same conditions after permeabilization of the cells with 0.1% Triton X-100 [13]. The enzymatic activity corresponding to canonical DPP-IV (CD26) was calculated by subtracting the residual activity (insensitive to a specific DPP-IV inhibitor sitagliptin, BioVision France) from the whole DPP-IV-like enzymatic activity.…”

Section: Methodsmentioning

confidence: 99%

The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus

Sromova

Bušek

Posová

et al. 2016

Diabetes Research and Clinical Practice

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus

Sromova

Bušek

Posová

et al. 2016

Diabetes Research and Clinical Practice

Self Cite

View full text Add to dashboard Cite

“…The release of 7-amino-4-methylcoumarin was monitored at excitation and emission wavelengths of 380 and 460 nm, respectively (Spectrofluorimeter Perkin Elmer LS50B). The cell surface DPP-IV-like enzymatic activity in BMNC was determined as the activity of viable cells, the total DPP-IV-like enzymatic activity was measured under the same conditions after permeabilization of the cells with 0.1 % Triton X-100 [ 12 ].…”

Section: Methodsmentioning

confidence: 99%

“…Given the role of DPP-IV in T cell activation [ 10 ] and its ability to cleave numerous proinflammatory peptides involved in the pathogenesis of RA [ 5 ], several studies examined its possible significance in the disease progression. The results of these studies, including ours, have so far revealed (although variably) a decreased DPP-IV-like enzymatic activity in the mononuclear cells isolated from the synovial fluid of RA patients [ 11 , 12 ] as well as decreased blood plasma DPP-IV enzymatic activity/concentration [ 12 – 14 ]. Higher DPP-IV expression was reported in blood mononuclear cells and especially CD4+ T lymphocytes in RA patients with high disease activity compared to healthy controls [ 15 – 18 ].…”

Section: Introductionmentioning

confidence: 95%

“…Higher DPP-IV expression was reported in blood mononuclear cells and especially CD4+ T lymphocytes in RA patients with high disease activity compared to healthy controls [ 15 – 18 ]. The literature data on the association of these changes with the disease activity are inconsistent [ 12 , 14 , 18 , 19 ]. Furthermore, it is currently unclear whether the changes of DPP-IV in blood plasma and peripheral mononuclear cells relate to the disease activity on the intraindividual basis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intraindividual changes of dipeptidyl peptidase-IV in peripheral blood of patients with rheumatoid arthritis are associated with the disease activity

Sromova

Bušek

Šedová

et al. 2015

BMC Musculoskelet Disord

Self Cite

View full text Add to dashboard Cite

BackgroundDipeptidyl peptidase-IV (DPP-IV) is suggested to contribute to the pathogenesis of several autoimmune diseases. The aim of this study was to evaluate the association of DPP-IV presence in blood plasma and mononuclear cells with the disease activity in rheumatoid arthritis (RA).MethodsPatients with active RA (n = 27) were examined at the study enrolment and a follow-up examination was performed after the regression of the joint effusions and at least 6 months after the first investigation. The control group comprised patients with a noninflammatory joint disease, i.e. osteoarthritis (OA; n = 15). The DPP-IV-like enzymatic activity was measured by a kinetic fluorimetric method, the concentration of DPP-IV in the blood plasma was determined using ELISA and the expression of DPP-IV in leukocytes was assayed by flow cytometry.ResultsBlood plasma DPP-IV-like enzymatic activity (median ± SD 220.15 ± 83.6 pkat/mL in RA vs. 376.9 ± 144.9 pkat/mL in OA, p < 0.001) and concentrations (median ± SD 465.1 ± 215.6 ng/mL in RA vs. 953.3 ± 368.4 ng/mL in OA, p < 0.001) were lower in patients with active RA compared to OA. In RA patients, the blood plasma DPP-IV-like enzymatic activity negatively correlated with the CRP concentration (r = −0.39, p = 0.044). No significant differences were observed in the DPP-IV-like enzymatic activity and DPP-IV expression in blood mononuclear cells between the RA and OA groups. At follow-up, 18 RA patients had a less active disease as demonstrated by an improved DAS28 score. In this group, comparison of the entry and the follow-up values in individual patients revealed an increase of the blood plasma DPP-IV-like enzymatic activity (median ± SD 141 ± 46 % of the patient’s entry values, p = 0.011) and DPP-IV concentration (median ± SD 168 ± 25 %, of the patient’s entry values, p = 0.033). In contrast to the blood plasma, the DPP-IV expression in blood mononuclear cells was reduced in these patients as evidenced by a decrease in the cell surface DPP-IV-like enzymatic activity as well as the median fluorescence intensity of DPP-IV staining in lymphocytes (median ± SD 66 ± 56 %, p = 0.018 and 63 ± 31 % of the patient’s entry values, p = 0.005, respectively).ConclusionsThe association between RA activity and the changes in blood plasma and blood mononuclear cell DPP-IV in individual patients supports the possible relationship of DPP-IV to RA pathophysiology.

show abstract

“…Immune cells are another important constituent of the tumor microenvironment that may express DPP-IV, DPP8 and DPP9, but do not express FAP [135,165,166]. In cancer patients, changes in the DPP-IV levels are frequently seen in serum and in lymphocytes [80] and cytokines such as TGF-β may contribute to these changes in peripheral blood lymphocytes as documented in patients with oral cancer [167].…”

Section: Expression and Role Of Dipeptidyl Peptidase-iv And Related Pmentioning

confidence: 99%

Dipeptidyl Peptidase-IV and Related Proteases in Brain Tumors

Bušek¹,

Šedo²

2013

Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications

Self Cite

View full text Add to dashboard Cite

Dipeptidyl Peptidase-IV Activity and/or Structure Homologs (DASH): Contributing Factors in the Pathogenesis of Rheumatic Diseases?

Cited by 5 publications

References 10 publications

The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus

The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus

Intraindividual changes of dipeptidyl peptidase-IV in peripheral blood of patients with rheumatoid arthritis are associated with the disease activity

Dipeptidyl Peptidase-IV and Related Proteases in Brain Tumors

Contact Info

Product

Resources

About